



The enantioselective intramolecular Morita–Baylis–Hillman reaction catalyzed by amino acid-derived phosphinothiourea

Jing-Jing Gong, Kui Yuan, Hong-Liang Song, Xin-Yan Wu *

Key Laboratory for Advanced Materials and Institute of Fine Chemicals, East China University of Science and Technology, Shanghai 200237, China

ARTICLE INFO

Article history:

Received 21 November 2009

Received in revised form 25 January 2010

Accepted 26 January 2010

Available online 1 February 2010

Keywords:

Enantioselective organocatalysis
Intramolecular Morita–Baylis–Hillman reaction
Chiral phosphinothiourea
Amino acids
Enones

ABSTRACT

A series of chiral bifunctional phosphinothioureas derived from L-amino acids have been developed to promote the enantioselective intramolecular Morita–Baylis–Hillman reaction. The process afforded the cyclic hydroxyl enones with up to 84% ee and good yields under mild conditions.

© 2010 Elsevier Ltd. All rights reserved.

1. Introduction

The Morita–Baylis–Hillman (MBH) reaction,¹ one of the most fundamental and important processes for construction of C–C bonds and allylic alcohols, has received considerable interest in synthetic organic chemistry. In the last decades, there has been significant progress in developing efficient chiral catalysts for the enantioselective intermolecular MBH reactions.² However, the asymmetric intramolecular MBH reaction is in its infancy, only a few reports are known so far.³ The first enantioselective intramolecular MBH reaction was reported by Fráter's group in 1992, affording the product in 14% ee with 40% yield after a reaction time of 10 days.^{3a} Recently Miller and co-workers described an enantioselective intramolecular MBH reaction using a co-catalyst system involving pipercolinic acid and N-methylimidazole, the cyclic MBH products were obtained with up to 84% ee.^{3b} Hong et al. reported a highly enantioselective intramolecular MBH reaction of hept-2-enal catalyzed by proline, and the addition of imidazole as co-catalyst resulted in an inversion of enantioselectivity.^{3c} Therefore, development of asymmetric version of intramolecular MBH reactions is still a challenge.

In our previous work,⁴ we have successfully developed L-valine-derived phosphinothiourea **5a** for the asymmetric Morita–Baylis–

Hillman reaction between acrylates and aromatic aldehydes. Accordingly, other bifunctional phosphinothiourea compounds are high efficient in the intermolecular MBH reaction.⁵ For these reasons, we thought that it would be of interest to employ phosphinothiourea in the intramolecular Baylis–Hillman reaction. Herein, we report our results on the intramolecular MBH reaction catalyzed by amino acid-derived phosphinothioureas.


2. Results and discussion

The phosphinothioureas **5a–f** are easily accessible by condensation of chiral amino-phosphines **4** with 1.1 equiv of the corresponding isothiocyanate in CH₂Cl₂ at room temperature. The amino-phosphines **4** were prepared by degradation of 2-oxazolidinones **3**.⁷ Amino alcohols **2**,⁸ prepared by reduction of L-amino acids **1**, were converted quantitatively into compounds **3** via the addition with dimethylcarbonate (Scheme 1).

Initially the catalysts **5a–f** were examined in the intramolecular MBH reaction of substrate **6a**⁹ in CH₂Cl₂ at 25 °C. As shown in Table 1, the chiral scaffold of the organocatalysts significantly affected the enantioselectivity and the chemical yield. The L-phenylalanine-derived catalyst **5c** provided the desired product in higher ee and lower yield than the corresponding phosphinothioureas **5a** and **5b**, which derived from L-valine and L-alanine, respectively (entry 3 vs entries 1 and 2). The thiourea moiety of the catalysts also played an important role in achieving good yield and enantioselectivity. The L-phenylalanine-derived thiourea **5d** bearing strong electron-withdrawing

* Corresponding author. Tel.: +86 21 64252011; fax: +86 21 64252758.


E-mail address: xinyanwu@ecust.edu.cn (X.-Y. Wu).



Scheme 1. Synthetic route of the amino acid-derived phosphinothioureas.

substituent at phenyl group afforded the desired product in 83% yield and 76% ee, and it was more efficient than the corresponding thio-ureas **5c**, **5e**, and **5f** (entry 4 vs entries 3, 5, and 6). By comparison, **5d** was the optimum catalyst among the screened phosphinothioureas. The absolute configuration of the intramolecular MBH products is *R*-configuration, which was assigned by comparing the optical rotation value with those reported in the literature.^{3b}

Table 1
Screening of the phosphinothioureas for the intramolecular MBH reaction of **6a**^a



Entry	Catalyst	Time (h)	Yield ^b (%)	ee ^c (%)
1	5a	48	73	18
2	5b	12	72	16
3	5c	60	50	67
4	5d	12	83	76 ^d
5	5e	84	50	65
6	5f	84	45	56

^a The reactions were conducted with 10 mol % of organocatalyst, 0.2 mmol **6a** in 1 mL CH₂Cl₂ (0.2 M) at 25 °C.


^b Isolated yield.

^c Determined by HPLC using Chiralcel OD-H column.

^d [α]_D²⁰ +20.0 (c 0.30, CHCl₃).

Next, the solvents were investigated on this process with **5d** as the organocatalyst (Table 2). In CH₂Cl₂ and CHCl₃, the reaction proceeded quickly to provide the corresponding product with good yield and ee (entries 2 and 3). Although the reaction completed

Table 2
The effect of the solvents on the intramolecular MBH reaction^a



Entry	Solvent	Time (h)	Yield ^b (%)	ee ^c (%)
1	Toluene	32	70	48
2	CHCl ₃	13	88	74
3	CH ₂ Cl ₂	13	83	76
4	Ether	32	70	40
5	Ethyl acetate	40	73	45
6	THF	106	58	29
7	Acetone	40	73	40
8	EtOH	9	83	30
9	CH ₃ CN	32	70	48

^a The reactions were conducted with 10 mol % **5d**, 0.2 mmol **6a** in 1 mL solvent (0.2 M) at 25 °C.


^b Isolated yield.

^c Determined by HPLC using Chiralcel OD-H column.

within 9 h in EtOH, the enantioselectivity was poor (entry 8). In other screened solvents, the reactions afforded moderate yields (58–73%) and lower enantioselectivities (29–48% ee). Thus CH₂Cl₂ was selected as solvent for further investigation.

Furthermore, optimization of other reaction conditions, including the reaction temperature, the substrate concentration and the loading of catalyst were investigated (Table 3). The results indicated that the enantioselectivity was not sensitive to the reaction temperature, and the lower reaction temperature resulted in longer reaction time (entries 1–3). Reducing the substrate concentration from 0.2 M to 0.1 M, the enantioselectivity was decreased by only 2% ee (entry 1 vs entry 4). While the substrate concentration was increased to 0.3 M, the enantioselectivity was reduced obviously (entry 5). The loading of catalyst has a pronounced influence on chemical yield and enantioselectivity (entry 1 vs entries 6 and 7). In the presence of 5 mol % **5d**, the reaction was laggard. Surprisingly, using 20 mol % **5d** led to lower chemical yield due to the side-reaction. The results summarized in Table 3 prompted us to choose the reaction conditions using 10 mol % **5d** in CH₂Cl₂ at 25 °C to probe the scope of the intramolecular MBH reaction.

Table 3
Further optimization of reaction conditions^a




Entry	Temp (°C)	Concn (mol/L)	5d (mol %)	Time (h)	Yield ^b (%)	ee ^c (%)
1	25	0.2	10	13	83	76
2	0	0.2	10	35	76	71
3	40	0.2	10	13	85	72
4	25	0.1	10	12	80	74
5	25	0.3	10	12	86	60
6	25	0.2	5	108	82	65
7	25	0.2	20	12	69	66

^a The reactions were conducted in CH₂Cl₂.

^b Isolated yield.

^c Determined by HPLC using Chiralcel OD-H column.


Under the established optimal reaction conditions, the scope of the substrates in terms of intramolecular MBH reaction was investigated. As the results summarized in Table 4, the substrates with electron-rich substituent at the *para*-position of phenyl group (entries 1 and 2) could afford better enantioselectivity than those with electron-deficient substituent or without substituent at phenyl group (entries 5–12). In addition, the substrates bearing substituent at the *ortho*-position of phenyl group provided the products in excellent yields with poor enantioselectivity probably due to the *ortho* effect (entries 4 and 9). The thiophene analogue performed the MBH product with reduced yield and enantioselectivity (entry 12).

Table 4The substrates scope of the intramolecular MBH reaction^a

Entry	Ar	Time (h)	Yield ^b (%)	ee ^c (%)
1	4-MeOC ₆ H ₅	36	77	84
2	4-MeC ₆ H ₅	22	79	78
3	3-MeC ₆ H ₅	24	79	73
4	2-MeC ₆ H ₅	48	99	45
5	C ₆ H ₅	13	83	76
6	4-FC ₆ H ₅	12	76	75
7	4-BrC ₆ H ₅	12	86	71
8	3-BrC ₆ H ₅	20	93	66
9	2-BrC ₆ H ₅	20	100	5
10	4-ClC ₆ H ₅	12	82	68
11	Naphtha-2-yl	22	85	74
12	Thiophen-2-yl	24	63	59

^a The reactions were conducted with 10 mol% **5d**, 0.2 mmol **6** in 1 mL CH₂Cl₂ (0.2 M) at 25 °C.^b Isolated yield.^c Determined by HPLC using Chiralcel OD-H, Chiralpak AS-H or Chiralpak AD-H column.

The proposed mechanism of the phosphinothiourea catalyzed formation of cyclic hydroxyl enones is illustrated in Scheme 2. The phosphine attacks β-position of the Michael acceptor to form an enolate and the thiourea moiety activates the substrates **6** by forming hydrogen-bonds with the aldehyde carbonyl. Then the phosphinoyl associated enolate attacks the activated carbonyl from the *re*-face to give the product in an *R*-configuration.

**Scheme 2.** Proposed mechanism of phosphinothiourea catalyzed intramolecular MBH reaction.

3. Conclusion

In summary, a series of chiral phosphinothioureas have been synthesized starting from different amino acids, including *L*-valine, *L*-alanine, and *L*-phenylalanine. These bifunctional phosphinothioureas could promote the enantioselective intramolecular MBH reactions of ω-formyl-α,β-unsaturated carbonyl compounds, and the cyclic MBH products were obtained in up to 84% ee with good-to-excellent yields in dichloromethane at room temperature. Further efforts are underway with a focus on improving the reaction enantioselectivity and probing the full scope of this reaction.

4. Experimental

4.1. General methods

Melting points were taken without correction. Optical rotations were measured on a WZZ-2A digital polarimeter at the wavelength of the sodium D-line (589 nm). ¹H, ¹³C, and ³¹P NMR spectra were recorded on Bruker 500 or 400 spectrometer. ¹H NMR spectra were referenced to tetramethylsilane (0.00 ppm)

using CDCl₃ as solvent. ¹³C NMR spectra were referenced to solvent carbons (77.0 ppm for CDCl₃). ³¹P NMR spectra were referenced to an external H₃PO₄ signal (0.00 ppm). IR spectra were recorded on Nicolet Magna-I 550 spectrometer. High Resolution Mass spectra (HRMS) were recorded on Micromass GCT or KE465 LCT Premier/XE spectrometer. HPLC analysis was performed on Waters 510 with 2487 detector using Daicel Chiralcel OD-H, Chiralpak AS-H or Chiralpak AD-H column.

4.2. General procedure for synthesis of phosphinothiourea catalysts **5a–f**

To a solution of amino-phosphine compounds **4**⁶ (1.0 mmol) in 2.0 mL CH₂Cl₂ was added isothiocyanate (1.1 mmol) at room temperature, and the corresponding mixture was stirred at this temperature until the reaction completed (monitoring by TLC). The solvent was removed under reduced pressure and the residue was purified by column chromatography (petroleum ether/ethyl acetate) to afford the chiral phosphinothiourea compounds **5a–f**.

4.2.1. *L*-Valine-derived phosphinothiourea **5a.** White solid, 60% yield, mp: 54.6–55.7 °C; [α]_D²⁵ +32.1 (c 0.70, CHCl₃); ¹H NMR (500 MHz, CDCl₃): δ 7.80 (s, 1H), 7.49–7.42 (m, 4H), 7.40–7.35 (t, *J*=7.7 Hz, 2H), 7.34–7.23 (m, 7H), 7.07 (d, *J*=7.7 Hz, 2H), 5.97 (d, *J*=8.5 Hz, 1H), 4.59 (br, 1H), 2.44–2.38 (m, 1H), 2.32–2.24 (m, 1H), 2.17–2.09 (m, 1H), 0.87 (d, *J*=6.8 Hz, 3H), 0.83 (d, *J*=6.8 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃): δ 180.1, 138.0, 136.2, 133.0 (d, *J*=5.2 Hz), 132.8 (d, *J*=5.2 Hz), 130.0, 128.9, 128.6–128.5 (m), 126.9, 125.1, 58.4 (d, *J*=14.2 Hz), 31.8 (d, *J*=8.6 Hz), 31.2 (d, *J*=13.5 Hz), 18.9, 18.0; ³¹P NMR (162 MHz, CDCl₃, 85% H₃PO₄): δ –24.49; IR (KBr, cm^{–1}): ν 3229, 3056, 2957, 1598, 1540, 1494, 1043, 565; HRMS (EI) calcd for C₂₄H₂₇N₂PS ([M]⁺) 406.1633, found: 406.1635.

4.2.2. *L*-Alanine-derived phosphinothiourea **5b.** Colorless oil, 72% yield, [α]_D³² +50.5 (c 1.00, CHCl₃); ¹H NMR (400 MHz, CDCl₃): δ 8.59 (br, 1H), 7.55–7.47 (m, 2H), 7.45–7.27 (m, 10H), 7.28–7.20 (t, *J*=7.6 Hz, 1H), 7.16 (d, *J*=7.6 Hz, 2H), 6.22 (br, 1H), 4.76 (br, 1H), 2.54–2.45 (m, 1H), 2.41–2.32 (m, 1H), 1.30 (d, *J*=6.8 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃): δ 179.0, 138.3 (d, *J*=11.8 Hz), 137.8 (d, *J*=11.8 Hz), 136.4, 133.0, 132.9, 132.8, 132.7, 130.0, 128.9, 128.8, 128.7–128.2 (m), 126.8, 124.9, 49.6 (d, *J*=16.9 Hz), 36.1 (d, *J*=14.8 Hz), 21.7 (d, *J*=9.1 Hz); ³¹P NMR (162 MHz, CDCl₃, 85% H₃PO₄): δ –24.63; IR (KBr, cm^{–1}): ν 3370, 3208, 3048, 2964, 1595, 1528, 1494, 1478, 1449, 1429, 1318, 1248, 738, 693; HRMS (EI) calcd for C₂₂H₂₃N₂PS ([M]⁺) 378.1320, found: 378.1321.

4.2.3. *L*-Phenylalanine-derived phosphinothiourea **5c.** White solid, 68% yield, mp: 45.8–46.9 °C; [α]_D³¹ +20.5 (c 1.00, CHCl₃); ¹H NMR (500 MHz, CDCl₃): δ 7.78 (s, 1H), 7.51–7.43 (m, 2H), 7.40–7.26 (m, 10H), 7.25–7.14 (m, 4H), 7.08 (d, *J*=6.5 Hz, 2H), 6.90 (d, *J*=7.6 Hz, 2H), 5.96 (d, *J*=7.0 Hz, 1H), 4.59–4.55 (m, 1H), 3.20–2.59 (m, 2H), 2.37 (d, *J*=6.5 Hz, 2H); ¹³C NMR (100 MHz, CDCl₃): δ 179.4, 138.1–137.8 (m), 137.4, 136.2, 133.1–132.8 (m), 130.0, 129.5, 128.9, 128.7, 128.6, 126.9, 126.7, 125.1, 54.2 (d, *J*=15.9 Hz), 40.6 (d, *J*=8.7 Hz), 33.1 (d, *J*=14.9 Hz); ³¹P NMR (162 MHz, CDCl₃, 85% H₃PO₄): δ –24.51; IR (KBr, cm^{–1}): ν 3373, 3195, 3053, 3025, 2932, 1595, 1529, 1494, 1451, 1432, 1309, 1244, 733, 699; HRMS (EI) calcd for C₂₈H₂₇N₂PS ([M]⁺) 454.1633, found: 454.1634.

4.2.4. *L*-Phenylalanine-derived phosphinothiourea **5d.** White solid, 75% yield, mp: 109.6–111.0 °C; [α]_D³¹ +8.3 (c 0.90, CHCl₃); ¹H NMR (400 MHz, CDCl₃): δ 8.73 (br, 1H), 7.68 (s, 1H), 7.60 (s, 2H), 7.48–7.35 (m, 4H), 7.35–7.23 (m, 9H), 7.19 (d, *J*=6.8 Hz, 2H), 6.37 (br, 1H), 4.95 (br, 1H), 3.29–2.95 (m, 2H), 2.66–2.49 (m, 1H), 2.46–2.27 (m, 1H); ¹³C NMR (100 MHz, CDCl₃): δ 179.6, 138.7, 137.6, 137.5, 137.1, 136.9, 136.8, 132.9, 132.8, 132.7, 132.6, 129.3, 129.1, 129.0, 128.7 (d,

$J=7.2$ Hz), 127.0, 124.2, 123.9, 121.5, 119.2, 54.7, 40.9, 32.9; ^{31}P NMR (162 MHz, CDCl_3 , 85% H_3PO_4): δ –25.19; IR (KBr, cm^{-1}): ν 3212, 3035, 1540, 1496, 1471, 1455, 1384, 1335, 1289, 1176, 1127, 737, 695; HRMS (EI) calcd for $\text{C}_{30}\text{H}_{25}\text{F}_6\text{N}_2\text{PS}$ ($[\text{M}]^+$) 590.1380, found: 590.1385.

4.2.5. *L*-Phenylalanine-derived phosphinothiourea **5e.** White solid, 60% yield, mp: 53.1–54.7 °C; $[\alpha]_{\text{D}}^{25} +29.5$ (c 1.00, CHCl_3); ^1H NMR (400 MHz, CDCl_3): δ 8.80 (br, 1H), 7.54–7.44 (m, 2H), 7.44–7.36 (m, 2H), 7.36–7.28 (m, 6H), 7.28–7.23 (m, 5H), 7.15 (d, $J=6.8$ Hz, 2H), 6.90 (d, $J=8.4$ Hz, 2H), 6.06 (br, 1H), 4.95 (br, 1H), 3.17–2.99 (m, 2H), 2.53–2.37 (m, 2H); ^{13}C NMR (100 MHz, CDCl_3): δ 179.4, 138.0–137.6 (m), 137.3, 134.8, 133.0, 132.9, 132.8, 132.7, 132.2, 130.0, 129.5, 128.9, 128.8–128.4 (m), 126.8, 126.3, 54.3 (d, $J=15.5$ Hz), 40.6 (d, $J=8.5$ Hz), 33.5 (d, $J=14.3$ Hz); ^{31}P NMR (162 MHz, CDCl_3 , 85% H_3PO_4): δ –24.66; IR (KBr, cm^{-1}): ν 3371, 3265, 3054, 2917, 1521, 1489, 1456, 1430, 1093, 737, 695; HRMS (EI) calcd for $\text{C}_{28}\text{H}_{26}\text{ClN}_2\text{PS}$ ($[\text{M}]^+$) 488.1243, found: 488.1245.

4.2.6. *L*-Phenylalanine-derived phosphinothiourea **5f.** White solid, 65% yield, mp: 59.1–60.4 °C; $[\alpha]_{\text{D}}^{25} +23.5$ (c 1.00, CHCl_3); ^1H NMR (400 MHz, CDCl_3): δ 8.33 (br, 1H), 7.54–7.44 (m, 2H), 7.44–7.34 (m, 2H), 7.34–7.26 (m, 6H), 7.26–7.15 (m, 3H), 7.11 (d, $J=6.8$ Hz, 2H), 6.90 (d, $J=8.4$ Hz, 2H), 6.83 (d, $J=8.4$ Hz, 2H), 5.89 (br, 1H), 4.93 (br, 1H), 3.79 (s, 3H), 3.13–2.94 (m, 2H), 2.40 (d, $J=6.8$ Hz, 2H); ^{13}C NMR (100 MHz, CDCl_3): δ 180.0, 158.7, 138.4–137.7 (m), 137.3, 133.1, 132.9 (d, $J=5.8$ Hz), 132.7, 129.5, 128.8 (d, $J=2.1$ Hz), 128.7–128.4 (m), 127.6, 126.6, 115.1, 55.6, 54.0 (d, $J=16.0$ Hz), 40.5 (d, $J=8.7$ Hz), 33.1 (d, $J=14.5$ Hz); ^{31}P NMR (162 MHz, CDCl_3 , 85% H_3PO_4): δ –24.67; IR (KBr, cm^{-1}): ν 3368, 3190, 3054, 2959, 2830, 1608, 1509, 1430, 1239, 1164, 1027, 740, 702; HRMS (EI) calcd for $\text{C}_{29}\text{H}_{29}\text{N}_2\text{OPS}$ ($[\text{M}]^+$) 484.1738, found: 484.1736.

4.3. General procedure for the intramolecular MBH reaction

To a solution of phosphinothiourea **5d** (0.02 mmol, 11 mg) in CH_2Cl_2 (1.0 mL) was added substrates **6** (0.2 mmol) at 25 °C. The reaction mixture was stirred at 25 °C until the reaction completed (monitoring by TLC). The solvent was removed under reduced pressure and the residue was purified by a flash column chromatography to afford the intramolecular Baylis–Hillman adducts. The ee values were determined by HPLC analysis with a chiral column.

4.3.1. (*R*)-(6-Hydroxycyclohex-1-enyl)(phenyl) methanone.⁹ ^1H NMR (500 MHz, CDCl_3): δ 7.66 (d, $J=7.2$ Hz, 2H), 7.54 (t, $J=7.2$ Hz, 1H), 7.44 (t, $J=7.2$ Hz, 2H), 6.73 (t, $J=4.0$ Hz, 1H), 4.74 (d, $J=1.2$ Hz, 1H), 3.51 (d, $J=1.2$ Hz, 2H), 2.39–2.22 (m, 2H), 1.97–1.84 (m, 3H), 1.69–1.66 (m, 1H). HPLC analysis (OD-H column, $\lambda=254$ nm, eluent: hexane/2-propanol=95/5, flow rate: 1.0 mL/min): $t_{\text{R}}=9.9$ min (major), 11.8 min (minor); $[\alpha]_{\text{D}}^{20} +20.0$ (c 0.30, CHCl_3 , 76% ee).

4.3.2. (*R*)-(6-Hydroxycyclohex-1-enyl)(4-methoxyphenyl) methanone. ^1H NMR (400 MHz, CDCl_3): δ 7.71 (d, $J=8.8$ Hz, 2H), 6.94 (d, $J=8.8$ Hz, 2H), 6.66 (t, $J=4.0$ Hz, 1H), 4.71 (s, 1H), 3.88 (s, 3H), 3.60 (br s, 1H), 2.39–2.22 (m, 2H), 1.95–1.85 (m, 3H), 1.69–1.65 (m, 1H); ^{13}C NMR (100 MHz, CDCl_3): δ 198.1, 163.0, 144.7, 139.8, 131.8, 130.2, 113.5, 64.2, 55.4, 29.8, 26.2, 17.4; IR (KBr, cm^{-1}): ν 3440, 2936, 1635, 1599, 1509, 1257, 1173, 1028, 767; HRMS (ESI) calcd for $\text{C}_{14}\text{H}_{16}\text{O}_3\text{Na}$ ($[\text{M}+\text{Na}]^+$): 255.0997, found: 255.0992. HPLC analysis (AS-H column, $\lambda=254$ nm, eluent: hexane/2-propanol=90/10, flow rate: 1.0 mL/min): $t_{\text{R}}=12.0$ min (major), 29.1 min (minor); $[\alpha]_{\text{D}}^{20} +57.5$ (c 0.20, CHCl_3 , 84% ee).

4.3.3. (*R*)-(6-Hydroxycyclohex-1-enyl)(4-tolyl) methanone.¹⁰ ^1H NMR (400 MHz, CDCl_3): δ 7.59 (d, $J=8.0$ Hz, 2H), 7.25 (d, $J=7.6$ Hz, 2H), 6.71 (t, $J=4.0$ Hz, 1H), 4.73 (s, 1H), 2.91 (br s, 1H), 2.42 (s, 3H), 2.40–

2.22 (m, 2H), 1.97–1.85 (m, 3H), 1.70–1.63 (m, 1H). HPLC analysis (AD-H column, $\lambda=254$ nm, eluent: hexane/2-propanol=90/10, flow rate: 1.0 mL/min): $t_{\text{R}}=14.7$ min (major), 16.1 min (minor); $[\alpha]_{\text{D}}^{20} +42.3$ (c 0.26, CHCl_3 , 78% ee).

4.3.4. (*R*)-(6-Hydroxycyclohex-1-enyl)(3-tolyl) methanone. ^1H NMR (400 MHz, CDCl_3): δ 7.47–7.43 (m, 2H), 7.36–7.30 (m, 2H), 6.73 (t, $J=4.0$ Hz, 1H), 4.74 (d, $J=2.4$ Hz, 1H), 3.51 (d, $J=2.4$ Hz, 1H), 2.41 (s, 3H), 2.39–2.20 (m, 2H), 1.97–1.82 (m, 3H), 1.69–1.60 (m, 1H); ^{13}C NMR (100 MHz, CDCl_3): δ 199.5, 146.8, 140.1, 138.0, 137.8, 132.7, 129.7, 128.0, 126.5, 63.9, 29.8, 26.3, 21.3, 17.4; IR (KBr, cm^{-1}): ν 3448, 2934, 2864, 1636, 1601, 1420, 1277, 1201, 1056, 986, 756; HRMS (ESI) calcd for $\text{C}_{14}\text{H}_{16}\text{O}_2\text{Na}$ ($[\text{M}+\text{Na}]^+$): 239.1048, found: 239.1046. HPLC analysis (AS-H column, $\lambda=254$ nm, eluent: hexane/2-propanol=90/10, flow rate: 0.9 mL/min): $t_{\text{R}}=7.1$ min (major), 23.1 min (minor).

4.3.5. (*R*)-(6-Hydroxycyclohex-1-enyl)(2-tolyl) methanone.^{3b} ^1H NMR (400 MHz, CDCl_3): δ 7.36–7.32 (m, 1H), 7.24–7.19 (m, 3H), 6.60 (t, $J=4.0$ Hz, 1H), 4.79 (s, 1H), 3.51 (s, 1H), 2.31 (s, 3H), 2.34–2.15 (m, 2H), 1.92–1.80 (m, 3H), 1.67–1.61 (m, 1H). HPLC analysis (AS-H column, $\lambda=254$ nm, eluent: hexane/2-propanol=90/10, flow rate: 0.9 mL/min): $t_{\text{R}}=6.4$ min (major), 12.6 min (minor); $[\alpha]_{\text{D}}^{27} +13.3$ (c 0.30, CHCl_3 , 45% ee).

4.3.6. (*R*)-(4-Fluorophenyl)(6-hydroxycyclohex-1-enyl) methanone. ^1H NMR (400 MHz, CDCl_3): δ 7.74–7.70 (m, 2H), 7.13 (t, $J=8.4$ Hz, 2H), 6.70 (t, $J=4.0$ Hz, 1H), 4.74 (s, 1H), 3.42 (s, 1H), 2.41–2.23 (m, 2H), 1.97–1.86 (m, 3H), 1.71–1.64 (m, 1H); ^{13}C NMR (100 MHz, CDCl_3): δ 197.7, 165.1 (d, $J=251.8$ Hz), 146.3, 140.0, 133.9 (d, $J=3.2$ Hz), 131.8 (d, $J=8.9$ Hz), 115.3 (d, $J=21.7$ Hz), 63.9, 29.8, 26.3, 17.4; IR (KBr, cm^{-1}): ν 3440, 2940, 2859, 1645, 1598, 1506, 1271, 1228, 987, 767; HRMS (ESI) calcd for $\text{C}_{13}\text{H}_{13}\text{O}_2\text{FNa}$ ($[\text{M}+\text{Na}]^+$): 243.0797, found: 243.0801. HPLC analysis (AD-H column, $\lambda=254$ nm, eluent: hexane/2-propanol=90/10, flow rate: 0.8 mL/min): $t_{\text{R}}=12.7$ min (minor), 14.0 min (major); $[\alpha]_{\text{D}}^{30} +25.0$ (c 0.32, CHCl_3 , 75% ee).

4.3.7. (*R*)-(4-Bromophenyl)(6-hydroxycyclohex-1-enyl) methanone.^{3b} ^1H NMR (400 MHz, CDCl_3): δ 7.60 (d, $J=8.4$ Hz, 2H), 7.54 (d, $J=8.4$ Hz, 2H), 6.71 (t, $J=4.0$ Hz, 1H), 4.75 (s, 1H), 2.57 (br s, 1H), 2.40–2.23 (m, 2H), 1.98–1.83 (m, 3H), 1.71–1.63 (m, 1H). HPLC analysis (AD-H column, $\lambda=254$ nm, eluent: hexane/2-propanol=90/10, flow rate: 1.0 mL/min): $t_{\text{R}}=19.4$ min (minor), 22.7 min (major); $[\alpha]_{\text{D}}^{30} +16.7$ (c 0.24, CHCl_3 , 71% ee).

4.3.8. (*R*)-(3-Bromophenyl)(6-hydroxycyclohex-1-enyl) methanone. ^1H NMR (400 MHz, CDCl_3): δ 7.78 (s, 1H), 7.66 (d, $J=8.0$ Hz, 1H), 7.57 (d, $J=8.0$ Hz, 1H), 7.32 (t, $J=8.0$ Hz, 1H), 6.73 (t, $J=4.0$ Hz, 1H), 4.74 (s, 1H), 3.37 (s, 1H), 2.42–2.23 (m, 2H), 1.97–1.81 (m, 3H), 1.69–1.63 (m, 1H); ^{13}C NMR (100 MHz, CDCl_3): δ 197.4, 147.7, 140.0, 139.7, 134.8, 132.0, 129.8, 127.8, 122.4, 63.7, 29.7, 26.5, 17.4; IR (KBr, cm^{-1}): ν 3446, 2925, 2855, 1652, 1636, 1418, 1078; HRMS (ESI) calcd for $\text{C}_{13}\text{H}_{13}\text{O}_2\text{BrNa}$ ($[\text{M}+\text{Na}]^+$): 302.9997, found: 302.9983. HPLC analysis (AD-H column, $\lambda=254$ nm, eluent: hexane/2-propanol=90/10, flow rate: 1.0 mL/min): $t_{\text{R}}=11.9$ min (minor), 13.5 min (major); $[\alpha]_{\text{D}}^{28} +11.3$ (c 0.40, CHCl_3 , 66% ee).

4.3.9. (*R*)-(2-Bromophenyl)(6-hydroxycyclohex-1-enyl) methanone. ^1H NMR (400 MHz, CDCl_3): δ 7.59 (d, $J=8.0$ Hz, 1H), 7.38–7.24 (m, 3H), 6.60 (t, $J=4.0$ Hz, 1H), 4.80 (t, $J=4.4$ Hz, 1H), 3.33 (s, 1H), 2.35–2.15 (m, 2H), 1.96–1.71 (m, 3H), 1.70–1.60 (m, 1H); ^{13}C NMR (100 MHz, CDCl_3): δ 198.5, 150.4, 140.6, 140.2, 133.0, 130.9, 128.6, 127.0, 119.4, 63.0, 29.7, 26.8, 17.4; IR (KBr, cm^{-1}): ν 3446, 2939, 2859, 1653, 1634, 1429, 1287, 1056, 986, 767. HRMS (ESI) calcd for $\text{C}_{13}\text{H}_{13}\text{O}_2\text{BrNa}$ ($[\text{M}+\text{Na}]^+$): 302.9997, found: 303.0005. HPLC

analysis (AS-H column, $\lambda=254$ nm, eluent: hexane/2-propanol=90/10, flow rate: 1.0 mL/min): $t_R=7.9$ min (major), 17.2 min (minor).

4.3.10. (R)-(4-Chlorophenyl)(6-hydroxycyclohex-1-enyl)methanone.^{3b} ^1H NMR (400 MHz, CDCl_3): δ 7.62 (d, $J=8.4$ Hz, 2H), 7.43 (d, $J=8.4$ Hz, 2H), 6.71 (t, $J=4.0$ Hz, 1H), 4.74 (s, 1H), 2.51 (br s, 1H), 2.42–2.24 (m, 2H), 1.98–1.88 (m, 3H), 1.71–1.64 (m, 1H). HPLC analysis (AS-H column, $\lambda=254$ nm, eluent: hexane/2-propanol=90/10, flow rate: 1.0 mL/min): $t_R=7.3$ min (major), 12.4 min (minor); $[\alpha]_D^{30}+23.3$ (c 0.30, CHCl_3 , 68% ee).

4.3.11. (R)-(6-Hydroxycyclohex-1-enyl)(naphthalen-2-yl)methanone. ^1H NMR (400 MHz, CDCl_3): δ 8.18 (s, 1H), 7.96–7.89 (m, 3H), 7.79–7.77 (m, 1H), 7.62–7.55 (m, 2H), 6.81 (t, $J=4.0$ Hz, 1H), 4.82 (s, 1H), 3.54 (s, 1H), 2.43–2.27 (m, 2H), 2.03–1.87 (m, 3H), 1.74–1.67 (m, 1H); ^{13}C NMR (100 MHz, CDCl_3): δ 199.2, 146.6, 140.3, 135.1, 135.0, 132.2, 130.6, 129.2, 128.2, 128.1, 127.8, 126.8, 125.4, 64.0, 29.9, 26.4, 17.5; IR (KBr, cm^{-1}): ν 3441, 2937, 1635, 1456, 1354, 1283, 1231, 1056, 989, 762; HRMS (ESI) calcd for $\text{C}_{17}\text{H}_{17}\text{O}_2$ ($[\text{M}+\text{H}]^+$): 253.1229, found: 253.1214. HPLC analysis (OD-H column, $\lambda=254$ nm, eluent: hexane/2-propanol=95/5, flow rate: 1.0 mL/min): $t_R=13.5$ min (major), 17.4 min (minor); $[\alpha]_D^{30}+31.4$ (c 0.35, CHCl_3 , 74% ee).

4.3.12. (R)-(6-Hydroxycyclohex-1-enyl)(thiophen-2-yl)methanone.^{3b} ^1H NMR (400 MHz, CDCl_3): δ 7.67 (d, $J=4.8$ Hz, 1H), 7.63 (d, $J=2.8$ Hz, 1H), 7.15–7.12 (m, 1H), 6.96 (t, $J=4.0$ Hz, 1H), 4.69 (s, 1H), 2.70 (s, 1H), 2.43–2.25 (m, 2H), 1.98–1.80 (m, 3H), 1.72–1.65 (m, 1H). HPLC analysis (AS-H column, $\lambda=254$ nm, eluent: hexane/2-propanol=90/10, flow rate: 1.0 mL/min): $t_R=9.5$ min (major), 17.0 min (minor); $[\alpha]_D^{30}+33.3$ (c 0.24, CHCl_3 , 59% ee).

Acknowledgements

We are grateful for the financial support from National Natural Science Foundation of China (20772029) and the Program for New Century Excellent Talents in University (NCET-07-0286).

References and notes

- For reviews, see: (a) Drewes, S. E.; Roos, G. H. P. *Tetrahedron* **1988**, *44*, 4653–4670; (b) Ciganek, E. *Org. React.* **1997**, *51*, 201–350; (c) Basavaiah, D.; Rao, P. D.; Hyma, R. S. *Tetrahedron* **1996**, *52*, 8001–8062; (d) Langer, P. *Angew. Chem., Int. Ed.* **2000**, *39*, 3049–3052; (e) Basavaiah, D.; Rao, A. J.; Satyanarayana, T. *Chem. Rev.* **2003**, *103*, 811–891.
- For recent reviews on enantioselective Morita–Baylis–Hillman reaction, see: (a) Basavaiah, D.; Rao, K. V.; Reddy, R. J. *Chem. Soc. Rev.* **2007**, *36*, 1581–1588; (b) Masson, G.; Housseman, C.; Zhu, J. *Angew. Chem., Int. Ed.* **2007**, *46*, 4614–4628; (c) Shi, Y.-L.; Shi, M. *Eur. J. Org. Chem.* **2007**, 2905–2916; (d) Declerck, V.; Martinez, J.; Lamaty, F. *Chem. Rev.* **2009**, *109*, 1–48; (e) Krishna, P. R.; Sachwani, R.; Reddy, P. S. *Synlett* **2008**, 2897–2912; (f) Ma, G.-N.; Jiang, J.-J.; Shi, M.; Wei, Y. *Chem. Commun.* **2009**, 5496–5514.
- (a) Roth, F.; Gyax, P.; Fráter, G. *Tetrahedron Lett.* **1992**, *33*, 1045–1048; (b) Ar-oyan, C. E.; Vasbinder, M. M.; Miller, S. J. *Org. Lett.* **2005**, *7*, 3849–3851; (c) Chen, S.-H.; Hong, B.-C.; Su, C.-F.; Sarshar, S. *Tetrahedron Lett.* **2005**, *46*, 8899–8903.
- Gong, J.-J.; Yuan, K.; Wu, X.-Y. *Tetrahedron: Asymmetry* **2009**, *20*, 2117–2120.
- (a) Shi, Y.-L.; Shi, M. *Adv. Synth. Catal.* **2007**, *349*, 2129–2135; (b) Yuan, K.; Zhang, L.; Song, H.-L.; Hu, Y.; Wu, X.-Y. *Tetrahedron Lett.* **2008**, *49*, 6262–6264; (c) Yuan, K.; Song, H.-L.; Hu, Y.; Wu, X.-Y. *Tetrahedron* **2009**, *65*, 8185–8190.
- Ito, M.; Osaku, A.; Kobayashi, C.; Shiibashi, A.; Ikariya, T. *Organometallics* **2009**, *28*, 390–393.
- Benoit, D.; Coulbeck, E.; Eames, J.; Motevalli, M. *Tetrahedron: Asymmetry* **2008**, *19*, 1068–1077.
- Mckennon, M. J.; Meyers, A. I. *J. Org. Chem.* **1993**, *58*, 3568–3571.
- Richards, E. L.; Murphy, P. J.; Dinon, F.; Fratucello, S.; Brown, P. M.; Gelbrich, T.; Hursthouse, M. B. *Tetrahedron* **2001**, *57*, 7771–7784.
- Seidel, F.; Gladysz, J. A. *Synlett* **2007**, 986–988.